58 related articles for article (PubMed ID: 19683050)
1. Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling.
Zhao Y; Okuyama M; Hashimoto H; Tagawa Y; Jomori T; Yang B
Toxicol In Vitro; 2010 Feb; 24(1):154-9. PubMed ID: 19683050
[TBL] [Abstract][Full Text] [Related]
2. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
[TBL] [Abstract][Full Text] [Related]
3. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
Hays T; Rusyn I; Burns AM; Kennett MJ; Ward JM; Gonzalez FJ; Peters JM
Carcinogenesis; 2005 Jan; 26(1):219-27. PubMed ID: 15447978
[TBL] [Abstract][Full Text] [Related]
4. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.
Nakamachi T; Nomiyama T; Gizard F; Heywood EB; Jones KL; Zhao Y; Fuentes L; Takebayashi K; Aso Y; Staels B; Inukai T; Bruemmer D
Diabetes; 2007 Jun; 56(6):1662-70. PubMed ID: 17360982
[TBL] [Abstract][Full Text] [Related]
5. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.
Hiuge A; Tenenbaum A; Maeda N; Benderly M; Kumada M; Fisman EZ; Tanne D; Matas Z; Hibuse T; Fujita K; Nishizawa H; Adler Y; Motro M; Kihara S; Shimomura I; Behar S; Funahashi T
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):635-41. PubMed ID: 17194889
[TBL] [Abstract][Full Text] [Related]
6. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.
Inoue I; Itoh F; Aoyagi S; Tazawa S; Kusama H; Akahane M; Mastunaga T; Hayashi K; Awata T; Komoda T; Katayama S
Biochem Biophys Res Commun; 2002 Jan; 290(1):131-9. PubMed ID: 11779144
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt.
Grabacka M; Plonka PM; Urbanska K; Reiss K
Clin Cancer Res; 2006 May; 12(10):3028-36. PubMed ID: 16707598
[TBL] [Abstract][Full Text] [Related]
8. Leptin induces hypertrophy through activating the peroxisome proliferator-activated receptor α pathway in cultured neonatal rat cardiomyocytes.
Hou N; Luo MS; Liu SM; Zhang HN; Xiao Q; Sun P; Zhang GS; Luo JD; Chen MS
Clin Exp Pharmacol Physiol; 2010 Nov; 37(11):1087-95. PubMed ID: 20738325
[TBL] [Abstract][Full Text] [Related]
9. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
[TBL] [Abstract][Full Text] [Related]
11. Effect of peroxisome proliferator-activated receptor alpha on human angiotensinogen promoter.
Shimamoto Y; Hirota K; Fukamizu A
Int J Mol Med; 2004 May; 13(5):729-33. PubMed ID: 15067378
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Cabrero A; Cubero M; Llaverías G; Jové M; Planavila A; Alegret M; Sánchez R; Laguna JC; Carrera MV
Metabolism; 2003 May; 52(5):652-7. PubMed ID: 12759900
[TBL] [Abstract][Full Text] [Related]
13. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.
François M; Richette P; Tsagris L; Fitting C; Lemay C; Benallaoua M; Tahiri K; Corvol MT
Arthritis Rheum; 2006 Apr; 54(4):1233-45. PubMed ID: 16572457
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway.
Kim J; Ahn JH; Kim JH; Yu YS; Kim HS; Ha J; Shinn SH; Oh YS
Exp Eye Res; 2007 May; 84(5):886-93. PubMed ID: 17343853
[TBL] [Abstract][Full Text] [Related]
15. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
16. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR.
Chen A; Xu J
Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G447-56. PubMed ID: 15486348
[TBL] [Abstract][Full Text] [Related]
17. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation.
Okayasu T; Tomizawa A; Suzuki K; Manaka K; Hattori Y
Life Sci; 2008 Apr; 82(15-16):884-91. PubMed ID: 18346759
[TBL] [Abstract][Full Text] [Related]
18. Involvement of PPARalpha in the growth inhibitory effect of arachidonic acid on breast cancer cells.
Bocca C; Bozzo F; Martinasso G; Canuto RA; Miglietta A
Br J Nutr; 2008 Oct; 100(4):739-50. PubMed ID: 18304389
[TBL] [Abstract][Full Text] [Related]
19. Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver.
Oishi K; Uchida D; Ishida N
FEBS Lett; 2008 Oct; 582(25-26):3639-42. PubMed ID: 18840432
[TBL] [Abstract][Full Text] [Related]
20. PPARalpha is a potential therapeutic target of drugs to treat circadian rhythm sleep disorders.
Shirai H; Oishi K; Kudo T; Shibata S; Ishida N
Biochem Biophys Res Commun; 2007 Jun; 357(3):679-82. PubMed ID: 17449013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
